论文部分内容阅读
Objective: Preoperative concurrent chemoradiotherapy (chemoRT) has been established as the standard of care for patients with cT3-4 rectal cancer.As an alternative strategy, we launched a randomized phase Ⅱ study to evaluate efficacy and toxicities of the modality of regular preoperative intensity-modulated chemoRT with a simultaneous integrated boost (SIB) or regular preoperative intensity-modulated chemoRT (regular).